TSX lower after index logs fresh record closing high
SOLANA BEACH, Calif. - Artelo Biosciences, Inc. (NASDAQ:ARTL), a micro-cap biotech company with a market capitalization of $9.18 million, announced Wednesday the publication of new preclinical data showing its proprietary CBD:tetramethylpyrazine cocrystal, ART12.11, demonstrated superior effectiveness in treating stress-induced depression and anxiety compared to CBD alone. The announcement comes as the stock has experienced significant volatility, dropping nearly 47% in the past week, according to InvestingPro data.
The peer-reviewed study, conducted with Western Ontario University researchers and published in Progress in Neuro-Psychopharmacology and Biological Psychiatry, found that ART12.11 reversed stress-induced behavioral deficits while achieving better oral bioavailability than conventional CBD formulations.
According to the research, the cocrystal enhanced activation of endocannabinoid and serotonergic systems in brain regions critical to mood regulation, including the prefrontal cortex and ventral hippocampus.
"ART12.11’s ability to improve stress-induced symptoms was not seen with CBD alone, the cocrystal coformer alone, or coadministration of CBD and the cocrystal conformer TMP," said Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo.
The company stated that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has agreed Artelo may rely on existing nonclinical and clinical evidence for CBD and TMP, potentially reducing development costs and accelerating progress toward human trials planned for next year.
ART12.11 is protected by a U.S. composition of matter patent enforceable until December 2038, which has been granted or validated in 19 additional countries, according to the company’s press release statement.
Artelo Biosciences is a clinical-stage pharmaceutical company focused on developing treatments for cancer, pain, and neurological conditions by modulating lipid-signaling pathways.
In other recent news, Artelo Biosciences announced the completion of a $3 million public offering of common stock. The offering included 640,924 shares priced at $4.40 per share and pre-funded warrants for an additional 40,894 shares. This capital raise has sparked some uncertainty, leading D. Boral Capital to downgrade Artelo Biosciences’ stock from Buy to Hold. The downgrade was influenced by the company’s recent financial maneuvers, including what was described as a "confusing crypto-related initiative."
Additionally, Artelo Biosciences reported interim results from its Phase 2 Cancer Appetite Recovery Study (CAReS) for ART27.13, a treatment aimed at improving the quality of life for cancer patients suffering from anorexia-cachexia syndrome. The trial included 18 patients with significant weight loss, primarily those with lung and gastrointestinal cancers. The company also recently launched a public offering of its common stock, with R.F. Lafferty & Co., Inc. serving as the sole book-running manager. These developments highlight Artelo’s ongoing efforts in both financial and clinical advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.